Trial Profile
Pradaxa Initiation Post-Stroke Study: SITS-Pradaxa 1. A Retrospective Analysis From the SITS-AF Registry on Treatment Initiation of Dabigatran Etexilate in Non-valvular Atrial Fibrillation Patients Hospitalized With Acute Ischemic Stroke
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jul 2020
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Acronyms SITS-Pradaxa 1
- Sponsors Boehringer Ingelheim
- 01 Jul 2019 Status changed from active, no longer recruiting to completed.
- 16 Apr 2019 Planned End Date changed from 1 Apr 2019 to 17 Jun 2019.
- 16 Apr 2019 Planned primary completion date changed from 1 Apr 2019 to 17 Jun 2019.